Unassociated Document
United
States Securities And Exchange Commission
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date
of Report (Date of Earliest Event Reported): November 18,
2009
(November
13, 2009)
|
| |
|
ISORAY, INC.
(Exact
name of registrant as specified in its charter)
|
| |
|
|
|
Minnesota
(State
or other jurisdiction
of
incorporation)
|
001-33407
(Commission
File
Number)
|
41-1458152
(IRS
Employer
Identification
No.)
|
350 Hills Street, Suite 106,
Richland, Washington 99354
(Address
of principal executive offices) (Zip Code)
(509)
375-1202
(Registrant's
telephone number)
ITEM 1.01 Entry
into a Material Definitive Agreement
On
November 13, 2009, IsoRay Medical, Inc. ("Medical"), a wholly owned subsidiary
of IsoRay, Inc. (the "Registrant"), entered into a Distributor Agreement (the
"Agreement") with Inter V Medical, Inc., a Canadian company ("Inter V"), with
the Agreement having an effective date of November 10, 2009. Under
the Agreement, Inter V will be the exclusive distributor of Medical's Cesium-131
products in Canada, subject to loss of exclusivity if Inter V fails to meet
certain of its obligations under the Agreement. The Agreement will
expire on November 10, 2011 unless earlier terminated or renewed by the
parties.
ITEM
9.01 Exhibits
|
|
10.54
|
Distributor
Agreement, dated effective November 10, 2009, by and between IsoRay
Medical, Inc. and Inter V Medical, Inc. (confidential treatment requested
for redacted portions)
|
SIGNATURES
In
accordance with the requirements of the Exchange Act, the Registrant caused this
report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Dated: November
17, 2009
| |
IsoRay, Inc., a
Minnesota corporation |
|
| |
|
|
|
| |
By:
|
/s/ Dwight
Babcock |
|
| |
|
Dwight
Babcock, CEO
|
|